Hepion Pharmaceuticals (HEPA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HEPA Hepion Pharmaceuticals

Watchlist

0.6940
0.00000.00%

Close Nov 19 15:58 ET

0.6940
0.00000.00%

Pre 09:01 ET

4.83MMarket Cap-157P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

No Data

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

10-Q: Q3 2024 Earnings Report
SECNov 14 16:57 ET · Announcements
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
BenzingaOct 25 06:05 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaOct 18 08:09 ET
Hepion Pharmaceuticals, Pharma Two B Announce SEC Filing for Proposed Merger Transaction
MT NewswiresSep 4 11:15 ET
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Hepion PharmaceuticalsSep 4 00:00 ET
10-Q: Q2 2024 Earnings Report
SECAug 13 16:04 ET · Announcements

Comments

Trytosaveabit

Sep 4 08:28

Update! Watching for the particulars

$Hepion Pharmaceuticals (HEPA.US)$ Reuters· 3 mins ago1min
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

103365182

Jul 22 07:57

Trapped with Greed

$Hepion Pharmaceuticals (HEPA.US)$ Lost a bunch due to the pump & dump 📉 lesson learnt 😨

Trytosaveabit

Jul 22 07:08

News

$Hepion Pharmaceuticals (HEPA.US)$ Pharma Two B Announces Plans to Go Public via Merger With Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Trytosaveabit

Apr 19 18:19

A shame especially with the study was going well! Wonder how much SS’s driving price so low ended up steering investors away? It happens sadly!

$Hepion Pharmaceuticals (HEPA.US)$ Hepion ends Phase 2 study for NASH drug due to cash restraints!
Hepion Pharmaceuticals (NASDAQ:HEPA) said it has begun winding down its ASCEND-NASH Phase 2 study for its drug rencofilstat as it continues to explore strategic alternatives for the company.
“We are disappointed to announce the wind-down of our Phase 2 NASHtr...